Eli Lilly & Co. agreed to pay $25 million to settle Connecticut civil charges it marketed its antipsychotic drug Zyprexa for unapproved uses.
Connecticut Attorney General Richard Blumenthal sued Indianapolis-based Lilly last year alleging the company improperly marketed the drug to treat depression in children and other psychological afflictions.
In January 2009, Lilly pleaded guilty to a federal misdemeanor charge over its marketing of Zyprexa for treating elderly patients with Alzheimer”™s disease, and agreed to pay up to $1.4 billion to settle federal and state charges.
In the second quarter, Lilly had a $1.2 billion profit on revenue totaling $5.3 billion. First approved in 1996, U.S. sales of Zyprexa totaled $2.2 billion in 2008 for Lilly, whose patent on the drug expires in 2011.
